Natera Inc (NTRA) Shares Sold by Contrarius Investment Management Ltd
Contrarius Investment Management Ltd lessened its position in shares of Natera Inc (NASDAQ:NTRA) by 7.1% during the 2nd quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 449,310 shares of the medical research company’s stock after selling 34,353 shares during the quarter. Contrarius Investment Management Ltd owned 0.82% of Natera worth $8,456,000 at the end of the most recent reporting period.
A number of other institutional investors have also recently bought and sold shares of NTRA. Trexquant Investment LP purchased a new stake in shares of Natera in the first quarter worth about $119,000. MetLife Investment Advisors LLC purchased a new stake in shares of Natera in the fourth quarter worth about $124,000. A.R.T. Advisors LLC purchased a new stake in shares of Natera in the first quarter worth about $164,000. State Board of Administration of Florida Retirement System purchased a new stake in shares of Natera in the second quarter worth about $200,000. Finally, Paradigm Capital Management Inc. NY purchased a new stake in shares of Natera in the second quarter worth about $207,000. Institutional investors and hedge funds own 73.61% of the company’s stock.
A number of analysts have recently commented on the company. Zacks Investment Research downgraded Natera from a “buy” rating to a “hold” rating in a research note on Tuesday. TheStreet upgraded Natera from a “d” rating to a “c-” rating in a research note on Thursday, August 9th. Canaccord Genuity upped their target price on Natera from $25.00 to $29.00 and gave the stock a “buy” rating in a research note on Thursday. Craig Hallum upped their target price on Natera from $23.00 to $30.00 and gave the stock a “buy” rating in a research note on Thursday, August 9th. Finally, Piper Jaffray Companies upped their target price on Natera to $27.00 and gave the stock an “overweight” rating in a research note on Thursday, August 9th. One equities research analyst has rated the stock with a hold rating, six have given a buy rating and two have assigned a strong buy rating to the stock. Natera has a consensus rating of “Buy” and an average target price of $23.14.
Natera (NASDAQ:NTRA) last issued its quarterly earnings results on Wednesday, August 8th. The medical research company reported ($0.55) earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of ($0.55). The company had revenue of $63.07 million for the quarter, compared to the consensus estimate of $61.71 million. Natera had a negative return on equity of 752.93% and a negative net margin of 59.07%. Natera’s revenue for the quarter was up 20.6% on a year-over-year basis. During the same quarter in the prior year, the business posted ($0.55) earnings per share. research analysts predict that Natera Inc will post -2.05 EPS for the current fiscal year.
In other Natera news, COO Steven Leonard Chapman sold 86,919 shares of the stock in a transaction that occurred on Monday, June 25th. The stock was sold at an average price of $18.00, for a total transaction of $1,564,542.00. Following the transaction, the chief operating officer now owns 3,588 shares in the company, valued at $64,584. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CFO Michael Burkes Brophy sold 26,870 shares of the stock in a transaction that occurred on Monday, July 2nd. The stock was sold at an average price of $18.29, for a total value of $491,452.30. The disclosure for this sale can be found here. Insiders have sold 115,797 shares of company stock worth $2,080,794 in the last quarter. 13.18% of the stock is currently owned by company insiders.
Natera, Inc, a diagnostics company, provides preconception and prenatal genetic testing services. It primarily offers Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus typically with a blood draw from the mother; Vistara, a single-gene mutations screening test to identify single-gene disorder; Horizon carrier screening to determine carrier status for various genetic diseases that could be passed on to the carrier's children; and Spectrum pre-implantation genetic screening and Spectrum pre-implantation genetic diagnosis to analyze chromosomal anomalies or inherited genetic conditions during an in vitro fertilization cycle.
Read More: Understanding Relative Strength Index
Want to see what other hedge funds are holding NTRA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Natera Inc (NASDAQ:NTRA).
Receive News & Ratings for Natera Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Natera and related companies with MarketBeat.com's FREE daily email newsletter.